Gemeprost
From Wikipedia, the free encyclopedia
Gemeprost
|
|
Systematic (IUPAC) name | |
methyl (E)-7-[(1R,2S,3R)-3-hydroxy-2- [(E,3R)-3-hydroxy-4,4-dimethyl-oct-1-enyl]- 5-oxo-cyclopentyl]hept-2-enoate |
|
Identifiers | |
CAS number | |
ATC code | G02 |
PubChem | |
Chemical data | |
Formula | C23H38O5 |
Mol. mass | 394.545 g/mol |
SMILES | search in | ,
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Pessary |
Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is an analogue of prostaglandin E1.
[edit] Clinical use
In pessary form as the second drug in medical abortion regimen in the UK and Sweden. Gemeprost softens and dilates the cervix and stimulates the uterus to contract.
[edit] Side effects
Vaginal bleeding, cramps, nausea, vomiting, loose stools or diarrhea, headache, muscle weakness; dizziness; flushing; chills; backache; dyspnoea; chest pain; palpitations and mild pyrexia. Rare: Uterine rupture, severe hypotension, coronary spasms with subsequent myocardial infarctions.